We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » Webinar Recordings » Chinese Medicine: The Dangers of Deployment - Webinar Recording/Transcript

Other Options

Audio Recording/Transcript - Nov. 29, 2018

$287.00

Audio Recording/Transcript - Nov. 29, 2018

$258.00

Audio Recording/Transcript - Nov. 29, 2018

$244.00

Audio Recording/Transcript - Nov. 29, 2018

$230.00

Audio Recording/Transcript - Nov. 29, 2018

$215.00

Chinese Medicine: The Dangers of Deployment - Webinar Recording/Transcript

$287.00
Webinar Recordings

Product Details

Chinese Medicine: The Dangers of Deployment — The Impact on Pharmaceutical Regulatory and Quality Specialists

Do you have concerns about Chinese API’s and chemical intermediates? If so, you’re not the only one.

More than half of all valsartan products on the U.S. market have been recalled due to a probable cancer-causing chemical in the API. The recall shines a spotlight on growing U.S. and global dependence on China for APIs and chemical intermediates.

Talk of proposed tariffs on Chinese pharmaceuticals has raised concerns about the impact on the supply and price of drugs. Tariffs could be disruptive to the market since China is the sole global supplier of many APIs and chemical intermediates. Supply chain modification is burdensome and can affect quality and access to an unfettered supply.

And China wants to become the world’s pharmacy.  What do you need to know?

FDAnews has called on Rosemary Gibson — Senior Advisor at the Hastings Center and author of China Rx: Exposing the Risks of America’s Dependence on China for Medicine to discuss the real-world impact of Chinese medicine on public health and the scrutiny it’s undergoing. You’ll learn the following:

  • Three lessons from the valsartan case
  • Three questions to ask API suppliers to ensure GMP
  • The rationale for proposed tariffs on Chinese medical products 
  • Details of the industry response to tariffs on Chinese-made APIs and chemical intermediates
  • The importance of China’s goal to become the world’s pharmacy and the impact on the global supply chain and regulatory oversight

Order today to understand the risks and challenges posed by U.S. dependence on Chinese pharmaceuticals.

  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing